Trial Profile
Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-Resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Panobinostat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Sep 2018 Results published in the Clinical Cancer Research
- 24 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.